Supplemental Figure 5 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy

Supplemental Figure 5: Serum cytokines are not different at baseline in neoantigen versus wild-type-tumored mice. All mice were given either B16KVP or B16F10 tumors. Six days later, mice received 5 Gy TBI. The next day, mice did or did not receive naïve pmel-1 ACT. Five days later, serum was collected. (A) Comparison of serum cytokines in B16KVP versus B16F10-tumored mice without addition of ACT. Multiple Mann-Whitney tests were performed – Unpaired, Nonparametric Mann-Whitney test with corrections for multiple comparisons using the Holm-Sidak Method. P-value threshold of 0.05 was set. (NS denotes not significant, p-value > 0.05). (B) Heatmap depicting serum cytokine data of B16KVP and B16F10-tumored mice at baseline as well as with ACT.